Pay in 4 interest-free payments of $6.92 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
GLP-1 Agonists: Optimizing Therapy Across Clinical Scenarios (1.5 hours) CE/CME Course #: 25-396 Review clinical guidance on optimizing use of GLP-1 receptor agonists (RAs) for managing type 2 diabetes and weight loss, as well as their role in cardiovascular and kidney diseases
Muscle plays a distinct role in the body
Kroneis, T., Jonasson, E., Andersson, D., Dolatabadi, S
6. Is it suitable for direct application?+
When you start an obesity management medication, it's always in addition to lifestyle therapy, she said
Seven drugs have currently been approved for the treatment of Type 2 diabetes mellitus, including short-acting agents like exenatide and lixisenatide, as well as long-acting injectable agents such as albiglutide, dulaglutide, liraglutide, and semaglutide. GLP-1s regulate lipid metabolism, reducing the effects of hyperlipidemia and helping to lower the risk for both chronic kidney disease (CKD) and diabetic kidney disease. They have also been shown to reduce oxidative stress, which includes stimulating glomerular filtration and reducing vasoconstriction, slowing the progression of CKD. Limited data from clinical trials have been published on the effects of GLP-1 receptor agonists in individuals with post-liver transplant diabetes mellitus (PTDM)
US$ 28.55
US$ 22.48
US$ 24.70
US$ 24.44
